METHOD AND SYSTEM FOR CALCULATING ENERGY DOSES, PLATFORM FOR SHARING AND DISTRIBUTING ENERGY DOSES AND ENERGY DOSE

APPLICATION DEVICE The method (1000) comprises receiving (1010) parameters from an initial user; retrieving (1020) from a database (110) an initial dose based on the parameters of the initial user; adjusting (1030) the initial dose based on parameters of the initial user and a simulation of an effect of the initial dose on a standard organism, generating an adjusted initial dose; receiving (1040) feedback from the initial user regarding the effect of the adjusted initial dose; calculating (1050) a final dose based on the feedback from the initial user and the adjusted initial dose; receiving (1060) feedback from a target user regarding the effect of the final dose; calculating (1070) an adjusted final dose based on the feedback from the target user and the final dose.

A method of preventing damage to non-neoplastic, e.g. healthy cells, by irradiating the non-neoplastic cells with a low-dose radiation is provided. The method initiates a protective cellular response which prevents later damage to non-neoplastic cells by radiotherapy and an immune response against neoplastic cells. The method of preventing damage to non-neoplastic cells is provided where the low-dose radiation is interspersed with a high dose sessions which themselves are varied through the weekly schedule.

A method of preventing damage to non-neoplastic, e.g. healthy cells, by irradiating the non-neoplastic cells with a low-dose radiation is provided. The method initiates a protective cellular response which prevents later damage to non-neoplastic cells by radiotherapy and an immune response against neoplastic cells. The method of preventing damage to non-neoplastic cells is provided where the low-dose radiation is interspersed with a high dose sessions which themselves are varied through the weekly schedule.

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a virion in the body fluid to form an antibody-virion complex, wherein the antibody comprises a tag sensitive to an illumination; removing the antibody-virion complex from the body fluid using an illumination source; and returning the body fluid to the patient. Other aspects are described and claimed.

The present disclosure provides a pathogen inactivation method, which is low-frequency sonication together with illumination of a photosensitizer-containing blood sample; and the low-frequency sonication is conducted at a frequency of 15-500 KHz. Through the combination of sonication and photochemical pathogen inactivation technology that enhance and complement each other, the blood pathogen inactivation method provided by the present disclosure enhances a pathogen inactivation effect, reduces a dosage of the photosensitizer, photosensitizer-related blood quality damage, energy demand for the illumination, and pathogen inactivation treatment time, increases the blood illumination thickness for effective pathogen inactivation, saves illumination bag materials, shortens the size of illumination equipment, saves costs, and helps the pathogen inactivation technology go to the market.

The present disclosure provides a pathogen inactivation method, which is low-frequency sonication together with illumination of a photosensitizer-containing blood sample; and the low-frequency sonication is conducted at a frequency of 15-500 KHz. Through the combination of sonication and photochemical pathogen inactivation technology that enhance and complement each other, the blood pathogen inactivation method provided by the present disclosure enhances a pathogen inactivation effect, reduces a dosage of the photosensitizer, photosensitizer-related blood quality damage, energy demand for the illumination, and pathogen inactivation treatment time, increases the blood illumination thickness for effective pathogen inactivation, saves illumination bag materials, shortens the size of illumination equipment, saves costs, and helps the pathogen inactivation technology go to the market.

The present disclosure relates to methods that enable the continuous formation of droplets and dehydration of droplets to provide pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled continuous droplet formation and dehydration that produce circular particles having low internal void spaces comprising bioactive therapeutic biologies.

The present disclosure relates to methods that enable the continuous formation of droplets and dehydration of droplets to provide pharmaceutically relevant particles that can be used for therapy. In particular, the methods disclosed herein allow the controlled continuous droplet formation and dehydration that produce circular particles having low internal void spaces comprising bioactive therapeutic biologies.

In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.

In one embodiment, the application discloses a method for the treatment of cancer in a patient, the method comprises a vaccination of the patient with a vaccine, wherein the vaccine comprises an effective amount of mammalian pluripotent stem cells obtained from an embryonic source or obtained by reprogramming of somatic cells from the patient, wherein the vaccination comprising the step of administering a mammalian pluripotent stem cells to the patient in need thereof; and vaccine formulations for use in the treatment of cancer.